– USA, MD – GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced the appointment of Dr. Thomas Fuchs to its board of directors.
About Dr. Thomas Fuchs
As the SVP and Chief AI Officer at Lilly, Dr. Fuchs provides vision, strategic direction, and overall leadership of AI initiatives for drug discovery, clinical trials, manufacturing, commercial activities, and internal functions. He also identifies, builds, and manages AI and machine learning solutions to help Lilly deliver medicines to patients around the world. Before joining Lilly, he was the Dean and inaugural Department Chair for AI and Human Health at Mount Sinai, Director of the Hasso Plattner Institute for Digital Health at Mount Sinai, and the endowed Barbara T. Murphy Professor for AI and Computational Pathology at the Icahn School of Medicine at Mount Sinai. Before Mount Sinai, Dr. Fuchs held positions at Memorial Sloan Kettering Cancer Center, NASA’s Jet Propulsion Laboratory, and the California Institute of Technology and founded three companies, including Paige AI. Dr. Fuchs holds a doctoral degree in machine learning from ETH Zurich and a master’s in technical mathematics from Graz Technical University in Austria.
About GeneDx
At GeneDx, we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest, rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies.
For more information: https://www.genedx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.